Plain-English translation of NCT07196722 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to see how well it works and how safe it is for people with moderate to severe Crohn's disease—a long-term condition that causes painful inflammation in the digestive tract. The study will compare the medication at two different doses against a placebo (a dummy pill with no active medicine) to figure out which works best. Researchers are recruiting about 1,092 people to participate.
Current treatments don't work well enough for everyone with moderate to severe Crohn's disease, and some patients can't tolerate the medications available today. This trial is testing whether this new treatment could offer another option for people whose symptoms aren't controlled by existing therapies.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the medication at one of two doses, or a placebo, for up to 12 weeks during an initial treatment phase. During this time, you'll have regular clinic visits for check-ups, bloodwork, and possibly endoscopy to see how the treatment is working. Depending on how you respond at week 12, you may continue or switch to a different treatment in a second phase of the study. The entire trial will involve multiple visits over several months.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States